A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC)

被引：0
|
作者：
Ko, A. H. [1 ]
Dito, E. [1 ]
Schillinger, B. [1 ]
Venook, A. P. [1 ]
Bergsland, E. K. [1 ]
Korn, W. M. [1 ]
Tempero, M. A. [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4516
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Andrew H. Ko
    Alan P. Venook
    Emily K. Bergsland
    R. Kate Kelley
    W. Michael Korn
    Elizabeth Dito
    Brian Schillinger
    Janet Scott
    Jimmy Hwang
    Margaret A. Tempero
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 1051 - 1057
  • [2] A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Ko, Andrew H.
    Venook, Alan P.
    Bergsland, Emily K.
    Kelley, R. Kate
    Korn, W. Michael
    Dito, Elizabeth
    Schillinger, Brian
    Scott, Janet
    Hwang, Jimmy
    Tempero, Margaret A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1051 - 1057
  • [3] Ascorbic acid plus gemcitabine (gem) and erlotinib (erl) in patients with metastatic pancreatic cancer (mPanc): Preliminary safety results
    Mitchell, E. P.
    Edman, J.
    Bazzan, A.
    Littman, S. J.
    Mahipal, A.
    Kandra, A. K.
    Hargrove, H.
    Kennedy, E. P.
    Levine, M.
    Monti, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Analysis of Blood Plasma Factors in the AVITA Phase III Randomized Study of Bevacizumab (bev) With Gemcitabine-Erlotinib (GE) in Patients (pts) With Metastatic Pancreatic Cancer (mPC)
    Van Cutsem, E.
    Jayson, G.
    Dive, C.
    Dilba, P.
    de Haas, S.
    Wild, N.
    Delmar, P.
    Scherer, S. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S95 - S96
  • [5] A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer
    Renouf, D. J.
    Tang, P. A.
    Hedley, D.
    Chen, E.
    Kamel-Reid, S.
    Tsao, M. S.
    Tran-Thanh, D.
    Gill, S.
    Dhani, N.
    Au, H. J.
    Wang, L.
    Moore, M. J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (11) : 1909 - 1915
  • [6] Phase I/II trial of gemcitabine (Gem) plus irinotecan (CPT-11) for metastatic pancreatic cancer (MPC)
    Yamai, Takuo
    Ioka, Tatsuya
    Sueyoshi, Hironari
    Takada, Ryoji
    Fukutake, Nobuyasu
    Ashida, Reiko
    Katayama, Kazuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [7] Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
    Okusaka, Takuji
    Furuse, Junji
    Funakoshi, Akihiro
    Ioka, Tatsuya
    Yamao, Kenji
    Ohkawa, Shinichi
    Boku, Narikazu
    Komatsu, Yoshito
    Nakamori, Shoji
    Iguchi, Haruo
    Ito, Tetsuhide
    Nakagawa, Kazuhiko
    Nakachi, Kohei
    CANCER SCIENCE, 2011, 102 (02) : 425 - 431
  • [8] A phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
    Nakachi, K.
    Okusaka, T. O.
    Funakoshi, A. F.
    Ioka, T. I.
    Yamao, K. Y.
    Ohkawa, S. O.
    Boku, N. B.
    Komatsu, Y. K.
    Nakamori, S. N.
    Furuse, J. F.
    EJC SUPPLEMENTS, 2009, 7 (02): : 387 - 387
  • [9] Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
    Van Cutsem, Eric
    Vervenne, Walter L.
    Bennouna, Jaafar
    Humblet, Yves
    Gill, Sharlene
    Van Laethem, Jean-Luc
    Verslype, Chris
    Scheithauer, Werner
    Cosaert, Aijing Shang Jan
    Moore, Malcolm J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (13) : 2231 - 2237
  • [10] Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
    Van Cutsem, E.
    Li, C-P
    Nowara, E.
    Aprile, G.
    Moore, M.
    Federowicz, I.
    Van Laethem, J-L
    Hsu, C.
    Tham, C. K.
    Stemmer, S. M.
    Lipp, R.
    Zeaiter, A.
    Fittipaldo, A.
    Csutor, Z.
    Klughammer, B.
    Meng, X.
    Ciuleanu, T.
    BRITISH JOURNAL OF CANCER, 2014, 111 (11) : 2067 - 2075
12345